Please assess the completion status of the following clinical trial:

Trial Title: A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC~* Adequate pulmonary and cardiac function~* Available biopsy of primary tumor with adequate samples~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease~* Any prior therapy for lung cancer within 3 years.~* Prior treatment with anti-PD-1 or PD-L1 therapies~* History or risk of autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab (Type: EXPERIMENTAL): Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).